DSIP – 10 mg

buy dsip (Delta Sleep-Inducing Peptide) promotes deep, restorative slow-wave sleep, reduces sleep latency, improves sleep efficiency and architecture, helps normalize disrupted circadian rhythms, decreases stress hormone levels, and enhances overall recovery and daytime alertness, making it a targeted option for chronic insomnia, jet lag, shift work, or stress-related sleep disturbances.

DSIP Ships from Canada!

• 2-4 Day Delivery
• 3rd Party Tested by Maple Leaf Diagnostics
• 99.68% Purity (Verified)
• COA Available

DSIP is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) isolated from rabbit brain venous blood in 1977, known for increasing delta-wave EEG activity and promoting slow-wave sleep in species like rabbits, rats, mice, cats, and humans.

It enhances deep sleep stages, shortens sleep onset, improves sleep efficiency, and reduces wakefulness, with effects most pronounced in disrupted sleep patterns.

The exact mechanism remains unresolved after decades: no specific receptor, precursor gene, or biosynthetic pathway has been definitively identified.

Proposed pathways include modulation of multiple neurotransmitter systems (influencing serotonin, dopamine, norepinephrine, GABA, glutamate levels), possible involvement of NMDA receptors, alpha-1 adrenergic signaling (e.g., potentiating pineal acetyltransferase activity), inhibition of somatostatin release via dopaminergic routes, reduced ACTH/cortisol for stress buffering, and stimulated growth hormone or somatoliberin secretion.

These changes likely contribute to easier sleep initiation, deeper delta-dominant sleep, and adaptogenic/stress-protective effects without strong sedation.

It crosses the blood-brain barrier via a saturable transport mechanism, supporting peripheral administration efficacy.

Evidence comes mainly from preclinical models and limited human studies; large-scale clinical trials are lacking, and findings show dose- and context-dependent variability (U-shaped dose-response curve in some cases).

References: buy dsip

Primary Withdrawal Study (107 patients):

Dick P, Costa C, Fayolle K, Grandjean ME, Khoshbeen A, Tissot R. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. European Neurology. 1984;23(5):364-371. PubMed

Initial Pilot Study (67 patients):

Dick P, Grandjean ME, Tissot R. Successful treatment of withdrawal symptoms with delta sleep-inducing peptide. Neuropsychobiology. 1983;10(4):205-208. PubMed

Chronic Pain Study:

Larbig W, Gerber WD, Kluck M, Schoenenberger GA. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. European Neurology. 1984;23(5):372-385. PubMed

Clinical Sleep Studies:

Schneider-Helmert D, Schoenenberger GA. Effects of DSIP in man: Multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology. 1983;9(4):197-206.